STANFORD UNIVERSITY

Researchers release flagship dataset from AI-READI study on type 2 diabetes, revealing heterogeneity among patients and associations with environmental factors. The dataset, including environmental sensor data and health metrics, aims to be mined by AI for novel insights. Initial findings highlight the need for diverse, granular data to explore disease and health pathways.

Brendan, a Ph.D. in organic synthesis from Stanford, worked at Merck and co-founded 1200 Pharma at Caltech. He remains an investor, focusing on biotech stocks. NTLA is a high-risk investment, akin to a long-dated call option, with potential for substantial gains or losses based on the success of NTLA-2001 and 2002.

Social media influencers and telemedicine drive increased access to testosterone for women, with prescriptions rising 50% from 2013-2023. Middle-aged women seek testosterone for libido, energy, and muscle health, though FDA approval is lacking. Benefits are modest, with one additional satisfying sexual event per month reported. Safety concerns include side effects like acne and hair growth.

Ricky Kej's album 'Break of Dawn' nominated for 67th Grammy Awards in Best New Age, Ambient, or Chant Album category. The album focuses on mental wellness and the connection between inner peace and the environment, inspired by ancient Indian and Buddhist philosophy. Kej collaborates with Stanford Global Health and Stanford School of Bio Design for clinical trials on the album's health impact.

Scientists identified a drug (BBI-2779) targeting ecDNA, which drives survival in aggressive cancers, potentially improving treatment outcomes.

Stanford thoracic surgeons, led by Dr. Natalie Lui, are raising awareness about early lung cancer screening during Lung Cancer Awareness Month. Dr. Lui directs the Stanford Lung Cancer Screening Clinic, which aims to increase screening rates and provide comprehensive follow-up care. Despite USPSTF recommendations, screening rates remain low, highlighting the need for increased awareness and efforts.

Researchers release flagship dataset from AI-READI study on type 2 diabetes, revealing heterogeneity among patients and associations with environmental factors. The dataset, including environmental sensors, survey responses, and biologic variables, aims to be mined by AI for insights on risks and preventive measures. The study, supported by NIH, includes diverse participants and aims to gather data from a more racially and ethnically diverse population.

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.

New research reveals how circular extrachromosomal DNA (ecDNA) in nearly 1 in 5 cancers co-segregates during mitosis to drive tumor evolution, forming novel regulatory circuits that enhance oncogene expression and immune system suppression. This discovery led to the first therapeutic targeting of ecDNA in preclinical models, with a CHK1 inhibitor showing significant tumor regression in mice.